L
Lavinia Spain
Researcher at The Royal Marsden NHS Foundation Trust
Publications - 72
Citations - 4339
Lavinia Spain is an academic researcher from The Royal Marsden NHS Foundation Trust. The author has contributed to research in topics: Ipilimumab & Medicine. The author has an hindex of 17, co-authored 55 publications receiving 2910 citations. Previous affiliations of Lavinia Spain include University College Hospital & Box Hill Hospital.
Papers
More filters
Journal ArticleDOI
Management of toxicities of immune checkpoint inhibitors.
TL;DR: This article identifies the rates of common and uncommon irAEs associated with each immune checkpoint inhibitor (ICPI) and their timing of onset, focusing mainly on the experience in melanoma and lung cancer.
Journal ArticleDOI
Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal
Samra Turajlic,Samra Turajlic,Hang Xu,Kevin Litchfield,Andrew Rowan,Tim Chambers,José I. López,David Nicol,Tim O'Brien,James Larkin,Stuart Horswell,Mark Stares,Mark Stares,Lewis Au,Mariam Jamal-Hanjani,Ben Challacombe,Ashish Chandra,Steve Hazell,Claudia Eichler-Jonsson,Aspasia Soultati,Simon Chowdhury,Sarah Rudman,Joanna Lynch,Archana Fernando,Gordon Stamp,Emma Nye,Faiz Jabbar,Lavinia Spain,Sharanpreet Lall,Rosa Guarch,Mary Falzon,Ian Proctor,Lisa Pickering,Martin Gore,Thomas B.K. Watkins,Sophia Ward,Sophia Ward,Aengus Stewart,Renzo G. DiNatale,Maria F. Becerra,Ed Reznik,James J. Hsieh,Todd Richmond,George F. Mayhew,Samantha M. Hill,Catherine D. McNally,Carol Jones,Heidi Rosenbaum,Stacey Stanislaw,Daniel Burgess,Nelson Alexander,Charles Swanton,Charles Swanton +52 more
TL;DR: Clear-cell renal cell carcinoma (ccRCC) exhibits a broad range of metastatic phenotypes that have not been systematically studied to date, and 9p loss is identified as a highly selected event driving metastasis and ccRCC-related mortality.
Journal ArticleDOI
Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal
Samra Turajlic,Samra Turajlic,Hang Xu,Kevin Litchfield,Andrew Rowan,Stuart Horswell,Tim Chambers,Tim O'Brien,José I. López,Thomas B.K. Watkins,David Nicol,Mark Stares,Ben Challacombe,Steve Hazell,Ashish Chandra,Thomas J. Mitchell,Lewis Au,Claudia Eichler-Jonsson,Faiz Jabbar,Aspasia Soultati,Simon Chowdhury,Sarah Rudman,Joanna Lynch,Archana Fernando,Gordon Stamp,Emma Nye,Aengus Stewart,Wei Xing,Jonathan C. Smith,Mickael Escudero,Adam Huffman,Nik Matthews,Greg Elgar,Ben Phillimore,Marta Costa,Sharmin Begum,Sophia Ward,Sophia Ward,Max Salm,Stefan Boeing,Rosalie Fisher,Lavinia Spain,Carolina Navas,Eva Grönroos,Sebastijan Hobor,Sarkhara Sharma,Ismaeel Aurangzeb,Sharanpreet Lall,Alexander Polson,Mary Varia,Catherine Horsfield,Nicos Fotiadis,Lisa Pickering,Roland F. Schwarz,Bruno Silva,Javier Herrero,Nicholas M. Luscombe,Mariam Jamal-Hanjani,Rachel Rosenthal,Nicolai Juul Birkbak,Nicolai Juul Birkbak,Gareth A. Wilson,Gareth A. Wilson,Orsolya Pipek,Dezso Ribli,Marcin Krzystanek,István Csabai,Zoltan Szallasi,Zoltan Szallasi,Martin Gore,Nicholas McGranahan,Peter Van Loo,Peter Van Loo,Peter J. Campbell,James Larkin,Charles Swanton,Charles Swanton +76 more
TL;DR: The insights reconcile the variable clinical behavior of ccRCC and suggest evolutionary potential as a biomarker for both intervention and surveillance and identify genetic diversity and chromosomal complexity as determinants of patient outcome.
Journal ArticleDOI
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Frederick Arce Vargas,Andrew Furness,Kevin Litchfield,Kroopa Joshi,Rachel Rosenthal,Ehsan Ghorani,Isabelle Solomon,Marta H. Lesko,Nora Ruef,Claire Roddie,Jake Y. Henry,Lavinia Spain,Assma Ben Aissa,Andrew Georgiou,Yien Ning Sophia Wong,Myles Smith,Dirk C. Strauss,Andrew J. Hayes,David Nicol,Tim O'Brien,Linda Mårtensson,Anne Ljungars,Ingrid Teige,Björn Frendéus,TRACERx Melanoma,TRACERx Renal,TRACERx Lung consortia,Martin Pule,Teresa Marafioti,Martin Gore,James Larkin,Samra Turajlic,Charles Swanton,Karl S. Peggs,Sergio A. Quezada +34 more
TL;DR: The data suggest that the activity of anti-CTLA-4 in inflamed tumors may be improved through enhancement of FcγR binding, whereas poorly infiltrated tumors will likely require combination approaches.
Journal ArticleDOI
Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal
Thomas J. Mitchell,Samra Turajlic,Andrew Rowan,David Nicol,James H.R. Farmery,Tim O'Brien,Inigo Martincorena,Patrick S. Tarpey,Nicos Angelopoulos,Lucy R. Yates,Adam Butler,Keiran Raine,Grant D. Stewart,Ben Challacombe,Archana Fernando,José I. López,Steve Hazell,Ashish Chandra,Simon Chowdhury,Sarah Rudman,Aspasia Soultati,Gordon Stamp,Nicos Fotiadis,Lisa Pickering,Lewis Au,Lavinia Spain,Joanna Lynch,Mark Stares,Jon W. Teague,Francesco Maura,David C. Wedge,Stuart Horswell,Tim Chambers,Kevin Litchfield,Hang Xu,Aengus Stewart,Reza Elaidi,Stéphane Oudard,Nicholas McGranahan,István Csabai,Martin Gore,P. Andrew Futreal,James Larkin,Andy G. Lynch,Zoltan Szallasi,Charles Swanton,Peter J. Campbell +46 more
TL;DR: Analysis of whole genomes from 95 biopsies across 33 patients with clear cell renal cell carcinoma suggests that the number of cells with 3p loss capable of initiating sporadic tumors is no more than a few hundred.